Economic burden of HIV and TB/HIV coinfection in a middle-income country: a costing analysis alongside a pragmatic clinical trial in Brazil. by Teixeira de Siqueira-Filha, Noemia et al.
Teixeira de Siqueira-Filha, N; Militao de Albuquerque, MF; Cunha
Rodrigues, L; Legood, R; Costa Santos, A (2018) Economic burden of
HIV and TB/HIV coinfection in a middle-income country: a costing
analysis alongside a pragmatic clinical trial in Brazil. Sexually trans-
mitted infections. ISSN 1368-4973 DOI: https://doi.org/10.1136/sextrans-
2017-053277
Downloaded from: http://researchonline.lshtm.ac.uk/4647040/
DOI: 10.1136/sextrans-2017-053277
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
1 
 
The economic burden of HIV and TB/HIV co-infection in a middle-income country: a costing 
analysis alongside a pragmatic clinical trial in Brazil  
1 Noemia Siqueira-Filha PhD, 2Maria de Fatima Militao PhD, 1 Laura C Rodrigues PhD, 1 Rosa Legood 
PhD, 1Andreia C Santos PhD 
1London School of Hygiene and Tropical Medicine (LSHTM), UK; 2Centro de Pesquisa Aggeu 
Magalhaes, Fundação Oswaldo Cruz (FIOCRUZ-PE), Brazil 
Corresponding author: Noemia Teixeira de Siqueira Filha, LSHTM, 15-17, Tavistock Place, London, 
WC1H 9SH, United Kingdom, +44(0)2079272908, noemia.teixeira-filha@lshtm.ac.uk 
Sources of support: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) 
(470554/2013-4) and Fundação de Amparo à Ciência e Tecnologia do Estado de Pernambuco (APQ-
0184-4.06/13). Some of the investigators received partial support from the Conselho Nacional de 
Desenvolvimento Científico e Tecnológico (CNPq): Scholarship PQ-308491/2013-0 to Maria de 
Fatima Militao de Albuquerque; Scholarship 220144/2012-5 to Noemia Teixeira de Siqueira. 
Word count: 2,939 
Number of tables: 4 
Conflict of interest: We declare no competing interests. 
  
2 
 
Abstract 
Objective: The objective of this study is to measure the costs of people living with HIV (PLHIV) as 
well as active tuberculosis (TB/HIV), latent tuberculosis infection (LTBI/HIV) or without TB 
(HIV/AIDS). 
Methods: We analysed the costs through the entire pathway of care during the pre-diagnosis and 
treatment periods from the Brazilian Public Health System perspective. We applied a combination of 
bottom-up and top-down approaches to capture and estimate direct medical and non-medical costs. We 
measured mean cost per patient per type of care (inpatient, outpatient and emergency care) and disease 
category, HIV/AIDS, HIV/AIDS death, TB/HIV, TB/HIV death and LTBI/HIV. 
Results: Between March 2014 and March 2016 we recruited 239 PLHIV. During the follow-up 26 
patients were diagnosed and treated for TB and five received chemoprophylaxis for LTBI. During the 
pre-diagnosis and treatment period, the mean total costs for HIV or AIDS and AIDS death categories 
were US$1,558 and US$2,828, respectively. The mean total costs for TB/HIV and TB/HIV death 
categories were US$5,289.0 and US$8,281, respectively. The mean total cost for the LTBI/HIV 
category was US$882. 
Conclusions: TB/HIV patients impose a higher economic burden on the health system than HIV/AIDS 
and LTBI/HIV. Patients with LTBI/HIV were the lowest cost group among all disease categories, 
indicating that preventive TB treatment can avoid the further costs treating active TB. 
Funding: National Council of Technological and Scientific Development (CNPq) and Fundação de 
Amparo à Ciência e Tecnologia do Estado de Pernambuco (FACEPE). 
Clinical trial registration number: RBR-22t943 
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Key messages 
 TB/HIV patients can cost 3.4 more than those with HIV/AIDS alone. TB/HIV death 
can cost almost three times more than an AIDS death. 
 Patients with LTBI/HIV had lower costs than all the other disease categories.  
 Results can support policy planning and direct resource allocation for the Brazilian 
response to the HIV epidemic  
 The study could be a reference for economic evaluation for countries with similar socio-
economic and epidemiological characteristics.  
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INTRODUCTION 
The AIDS epidemic has affected 37 million people worldwide and caused 1.1 million deaths in 2015. 
Among these deaths, one in three was due to HIV associated tuberculosis (TB). Additionally, one-third 
of people living with HIV (PLHIV) presented latent tuberculosis infection (LTBI)1. The lack of, or 
delays in, diagnosis and treatment of active TB can explain the high mortality rate among co-infected 
patients2,3. The reduction of AIDS-related deaths is a milestone established by the United Nations 
through Sustainable Development Goal 3 (SDG 3)1,4 and tackling TB co-infection is a key vehicle for 
reducing AIDS-related deaths. The treatment of LTBI is also crucial for the reduction of TB incidence 
in PLHIV. Mathematical models have predicted that the scaling-up of LTBI treatment, together with 
the diagnosis and prompt treatment of active TB, can sharply reduce TB incidence5,6. 
However, the funding available to address AIDS/HIV and TB/HIV co-infection is insufficient and 
might affect the potential success of SDG 3. Recent estimates indicate that US$8.3 billion is needed 
annually to combat TB in low and middle-income countries. In 2015, US$6.6 billion was invested and 
only 6% of this fund was allocated in TB/HIV co-infection actions7. Therefore, costing analyses can 
play a key role in supporting the achievement of the SDGs in a sustainable way, especially with the 
reduction in the amount of funding available to combat both epidemics in recent years. In addition, the 
majority of high TB/HIV burden countries face both financial and human resource constraints. Thus, 
cost analyses are essential to inform better allocation of resources and to support economic evaluations 
and budget impact studies for decision making.  
The objective of this study is to estimate the costs of PLHIV with or without active or latent TB, from 
the symptomatic phase until the first year of treatment from the perspective of the Brazilian public 
health system. We thus aim to contribute to the literature on costs of interventions for the control of TB 
and HIV/AIDS.  
METHODS  
Study location 
The study was conducted in the city of Recife, capital of the state of Pernambuco. We conducted the 
data collection in the Correia Picanco Hospital (CPH). The hospital provides care for approximately 
60% of all individuals with HIV/AIDS in the state, carrying out almost 3,000 outpatient appointments 
a month, including emergency and inpatient care8. 
Study population, inclusion and exclusion criteria 
The cost study was conducted alongside a pragmatic clinical trial designed to evaluate the cost-
effectiveness of a protocol for TB diagnosis in PLHIV. The costing study followed the trial criteria: we 
included newly-diagnosed HIV infected patients, aged 18 years or over. Participants who were being 
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treated for TB at the time of enrolment or had been treated for TB in the previous 3 months were 
excluded, as the trial aimed to test a protocol for TB diagnosis. We also excluded patients who were 
treated in the private sector and only visited the hospital to collect medicines. Further details of the 
clinical trial can be found in the Supplement. 
Procedures 
The cost study was conducted from the health system perspective, during the first two years of the trial 
(March/2014 to March/2016). We applied a mix of bottom-up and top-down approaches to capture and 
estimate the direct costs9–11. We obtained drug prices from the Brazilian Ministry of Health (MoH) 
database12 and test costs from health system records13. Staff wages, hospital productivity and values of 
contracts and utility bills were collected from the CPH administrative division.  Further details on data 
collection and cost estimates are given in the Supplement and Tables S1 and S2. Costs were calculated 
in local currency (Real, 2015 prices) and converted to US dollars using an average exchange rate for 
the period of study as calculated by OANDA (R$1= US$0.34765)14. 
Interviews with patients were conducted by trained technical nurses during pre-admission at CPH. The 
interviews were intended to collect data on the use of medical resources at emergency and outpatient 
care during the HIV pre-diagnosis period, from the onset of the disease until diagnosis. Interviewers 
also collected data on demographic, socio-economic characteristics and lifestyle habits of individuals. 
For those who were diagnosed with TB or LTBI during the two-year data collection period, we 
considered the TB/HIV pre-diagnosis period as the time between TB first symptoms and its diagnosis. 
As LTBI/HIV patients do not present TB symptoms, we considered pre-diagnosis the period between 
the first HIV symptoms and LTBI diagnosis. 
Subsequent interviews were conducted at every patient appointment at CPH. Besides checking for TB 
or LTBI diagnosis, the interviewer also collected data on the use of medical resources at outpatient and 
emergency care and on hospitalisations at CPH and other health services sought by the patients during 
the treatment period. To assess the use of resources at inpatient care in both the pre-diagnosis and 
treatment period, we reviewed patients’ medical notes at CPH and other health services. Details of the 
drug scheme for TB and LTBI treatment can be found in the Supplement. 
Data cleaning and analysis 
Questionnaires were double entered in an Excel spreadsheet. The cost estimates were produced in Excel 
and statistical analyses in Stata/IC 14. The main outcomes were the cost per type of care (emergency, 
outpatient and inpatient care) and total costs (pre-diagnosis + treatment period) per patient per category 
of disease (HIV or AIDS, AIDS death, TB/HIV, TB/HIV death, LTBI/HIV). The mean was reported 
for all cost estimates as measures of central tendency, as well as the associated standard deviation (SD). 
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To test difference in proportions, we used the Chi square test for categorical variables or Fisher’s exact 
test when one or more cells had a frequency of five or less observations. For continuous variables with 
non-parametric distribution, we used the Wilcoxon-Mann-Whitney test. Differences in cost per 
category of patient were analysed using a Dunn’s test with Benjamini-Hochberg adjustment for multiple 
comparisons. All p-values below 0.05 were considered statistically significant. We used the mean 
imputation approach to handle costing missing data; this assigns the mean cost of each item, at each 
level of care, to the missing value15. In order to compare our results with studies conducted in other 
countries, we also presented our results in International Dollars ($) applying purchase power parity 
(2015 prices) (Table S5 and S6)16. Costs of the studies presented in the discussion section were updated 
to 2015 using USD inflation rate, estimated by the International Monetary Fund17 and converted  to 
international dollars applying World Bank indices 16. 
Sensitivity analysis 
A one-way sensitivity analysis was performed to assess uncertainties related to the parameters used. 
We varied the mean costs of TB/HIV, HIV/AIDS and LTBI/HIV per type of care by ± 50%, as we did 
not have information regarding the highest and lowest value for each cost item.  We varied the following 
direct medical cost parameters at emergency, outpatient and inpatient care: drugs, tests, medical 
appointment, bed days, ART and TB drugs. Results are presented in tornado diagrams to demonstrate 
the impact of each parameter change in the total cost.   
Ethics 
The study was approved by the Fundacao Oswaldo Cruz (No 279.324) and the London School of 
Hygiene and Tropical Medicine (Ref: 7371) ethics committees. All patients signed a consent form. The 
clinical trial was registered at Brazilian Registries for Clinical Trials (RBR-22t943). We attest that we 
have obtained appropriate permissions and paid any required fees for use of copyright protected 
materials. 
RESULTS  
In a two-year study period, 315 PLHIV were recruited, 15 patients were excluded at the randomisation 
stage, 25 were transferred to another health service and 37 were considered lost to follow-up. The final 
sample for this study was 239 PLHIV, with 79 patients in the control arm (72 HIV or AIDS, 7 TB/HIV, 
none LTBI/HIV) and 160 in the intervention arm (136 HIV or AIDS, 19 TB/HIV and 5 LTBI/HIV).  In 
total, during the follow-up period, 208 patients were treated for HIV or AIDS, 26 were diagnosed and 
treated for active TB/HIV co-infection and five were diagnosed and treated for LTBI/HIV (Figure S1). 
Tables 1, S3 and S4 show the baseline characteristics of the patients included in our analysis. In the 
HIV or AIDS and TB/HIV categories, most patients were male whilst most of the LTBI/HIV patients 
were female (p = 0·007). For all disease categories, most patients were in the 18-39 years age group and 
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most patients were literate with a minimum of four years of study (90% of the total sample). When 
compared with HIV or AIDS and LTBI/HIV, patients in the TB/HIV category presented higher rates of 
alcohol dependence (p = 0·009) and use of illicit drugs, crack (p = 0.002) and glue (p = 0·009).  
Treatment characteristics 
Patients in the TB/HIV category were seen more frequently at emergency care in both pre-diagnosis 
and treatment period, but frequency of use only differed from that of the HIV/AIDS category in the pre-
diagnosis period (p<0·001). The average length of hospitalisation during the treatment period was twice 
as high as that during pre-diagnosis period for both disease categories. Patients in the TB/HIV category 
presented lower CD4 counts (<200 cells/m3) at first appointment than the other categories (p = 0·009). 
LTBI/HIV and TB/HIV co-infected patients started ART later than HIV/AIDS patients (p = 0·003).  
Also, the proportion of deaths was higher among TB/HIV patients than HIV/AIDS patients (31% vs 
6%; p = 0·001) (Table 2).  
Cost per site of care 
During the pre-diagnosis period, the TB/HIV category had the highest costs at emergency, outpatient 
and inpatient care. The difference in the mean total costs was higher between the TB/HIV and 
HIV/AIDS categories: emergency care – US$419 vs US$ 109; outpatient care -  US$269 vs US$64. 
There was no hospitalisation among LTBI/HIV patients during the pre-diagnosis period and the mean 
total cost was higher for the TB/HIV patients than the HIV/AIDS patients, US$ ,532 and US$1,710, 
respectively. 
During the treatment period, the LTBI/HIV category patients did not have emergency care and only one 
patient was hospitalised (US$ 549). At outpatient care, all patients presented similar costs, with the 
HIV/AIDS patients presenting a slightly higher mean total cost: HIV or AIDS – US$777; TB/HIV - 
US$687; LTBI/HIV – US$609. At inpatient care, the mean total cost for TB/HIV was almost double 
that of the HIV/AIDS patients, US$4,372 vs US$2,850 (Table 3). 
Costs per patient category 
The category TB/HIV death presented the highest mean costs (pre-diagnosis, treatment and total) when 
compared with other categories. The mean total direct cost (pre-diagnosis + treatment period) of 
TB/HIV death was almost three times that of the mean cost of HIV or AIDS death: US$ 8,281 vs US$ 
2,828. When compared with the LTBI/HIV category, the mean direct cost of the TB/HIV category was 
more than five times higher; US$5,289 vs US$882 (Table 4). Statistical significance in the total costs 
(pre-diagnosis plus treatment period) was found for HIV or AIDS vs TB/HIV (p <0·0001), TB/HIV vs 
LTBI/HIV (p = 0·0015) and AIDS death vs TB/HIV death – (pre-diagnosis period only) (p = 0.0016). 
Table S7 shows the complete statistical analysis for the pre-diagnosis, treatment period and total cost.   
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Sensitivity analysis 
During the pre-diagnosis period, the cost item ‘medical appointment’ had the highest impact on the total 
cost for all types of care and disease categories. During the treatment period, the cost item ‘ART’ had 
highest impact on outpatient care for HIV or AIDS and TB/HIV categories. Medical appointment also 
had the highest impact on all other types of care. Tornado diagrams are presented in Figure S2. 
DISCUSSION 
TB/HIV patients cost 3.4 times more than those with HIV/AIDS and those who died due to TB/HIV 
co-infection cost almost three times more than those who died due to AIDS. In the meantime, patients 
with LTBI/HIV presented the lowest cost among all disease categories, indicating the treatment of 
patients at the latent phase can be cheaper than the active phase. The highest cost for TB/HIV was 
mainly due to inpatient care. Our findings reinforce the hypothesis that TB/HIV patients have more 
complications during treatment and, therefore, are hospitalised more frequently and treated with more 
expensive drugs18. Indeed, in our study, the cost of drugs and tests at inpatient care was higher for 
TB/HIV than HIV or AIDS. Another study carried out in Sudan found greater costs of hospitalisation 
among TB/HIV co-infection than TB/HIV negative patients. Nevertheless, the updated costs of 
hospitalisation in international dollars (2015) found in the Sudanese study were lower than the costs 
found in our study: $2,847 vs $6,801. The mean treatment cost of TB/HIV category was also lower 
compared with our study: $1,568 vs $ 6,34119. 
Other studies carried out in low- and middle-income countries reported similar or lower costs compared 
with our study. In Burundi, the mean annual cost to treat HIV/AIDS patients was $3,223 vs $ 2,032 in 
Brazil20. In Thailand the mean costs to treat TB/HIV patients was $1,535 vs $6,341 in Brazil21. In China, 
TB was the most expensive opportunistic infection in PLHIV after Cytomegalovirus infection, $647 
and $3,189, respectively22. In South Africa, the cost of hospitalised TB/HIV patients was $3,925. In the 
same study, the treatment of other common diseases in PLHIV presented higher costs, such as endocrine 
and metabolic disease ($5,260) and gastrointestinal disease ($4,889)23. Another South African study 
reported hospitalisation costs of TB/HIV patients varying from $2,541 to $4,885 according to type of 
TB, ART status and ward (adult and paediatric)24.  
In contrast to ART, the cost of TB drugs was lower at outpatient care. Furthermore, in Brazil, TB drug 
costs in HIV patients were lower than in other low and middle-income countries: $36 vs $50 in Burundi; 
$338 in China and $397 in Thailand20–22. In Sudan, the cost of TB drugs in PLHIV varied from $113 to 
$380 according to TB outcome and TB drug scheme19.  
The higher cost of TB/HIV can be explained by the higher proportion of patients presenting with CD4 
counts below 200 cells/m3, which indicates that co-infected patients are arriving at the health service at 
a more advanced stage of HIV infection for the first appointment. Another hypothesis is the delay in 
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TB diagnosis and treatment, which can cause a deterioration in the patient’s health and, consequently, 
increase treatment costs. Also, analysing the lifestyle of TB/HIV patients, we perceive higher rates of 
lifestyle vulnerability, such as drug and alcohol dependency. All these aspects can be linked to rising 
costs and worse outcomes, such as higher mortality and hospitalisation rates, within TB/HIV patients. 
UNAIDS states that the achievement of the Fast-Track Target prevention and treatment tools could 
decrease the number of HIV-related deaths, including TB deaths in HIV patients, by 81% up to 203025.  
In our study, only five out of 213 HIV/AIDS patients received IPT to prevent TB. During the study 
period, the hospital faced a shortfall in the provision of TST reagent and IPT was based only on the 
history of contact with TB patients and a medical practitioner’s decision as to whether treatment was 
offered. Our estimates showed that the mean cost to treat LTBI/HIV was much cheaper than the 
treatment of TB/HIV (US$882 vs US$5,289). The treatment is strongly recommended by WHO to 
prevent TB in PLHIV and should be provided to those who are unlikely to have TB, regardless of TST 
readings26,27. Thus, the scaling-up of IPT for all PLHIV should be adopted to prevent deaths and save 
costs related to treatment of TB/HIV co-infection. 
The trial design raises some limitations to our study, in spite of advantages that it also brings, such as 
reduction in potential bias due to the randomisation, practicality of the data collection, and collection 
of costing data and outcomes at patient-level28. In our study, the gene Xpert test, which is not routinely 
implemented in the hospital, was used in patients from the intervention arm. However, it was applied 
at outpatient care and only nine TB suspect patients were able to perform the test due to lack of sputum. 
Thus, this cost does not seem to influence the final cost of the disease in outpatient care. Furthermore, 
we cannot generalise our results to countries where costs are likely to be different; thus, our results have 
a low external validity. The artificial environment created by a trial (patient tracing, for instance) is also 
another issue to be considered when extrapolating our data, although the pragmatic design is likely to 
reduce the limitations created by this artificial environment28. Another limitation relates to the price of 
laboratory tests collected from the Brazilian MoH database. These values represent amounts paid to 
providers to partially cover their laboratory costs, and do not represent the full costs of the tests. In our 
sensitivity analysis, these costs did not present an important impact on the cost estimates by disease 
categories. The small sample size, especially for TB/HIV and LTBI/HIV patients could also be a 
limitation for the generalisability of our results. 
Successful experience of TB/HIV control in another Latin American country, Peru, was evaluated. The 
Community-Based Accompaniment with Supervised Antiretroviral (CASA) was a cost-saving 
intervention and decreased the rate of death from 30% to 9%29. In Brazil, the strengthening of 
collaborative TB/HIV activities, early and accurate TB diagnosis, IPT and other policies addressing 
vulnerable populations can save further costs for the public health system and can contribute to the 
achievement of SDG and UNAIDS Fast-Track goals in a sustainable and consolidated way. 
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In conclusion, TB/HIV patients impose a higher economic burden on the public health system than HIV 
or AIDS and LTBI/HIV patients in all pathways of care. Further studies should address the costs of 
scaling-up of IPT. It is important that other studies addressing the budget impact of social protection 
programmes for TB/HIV patients and costs of intensive TB case finding algorithms and more accurate 
TB diagnosis among HIV patients are carried out in the Brazilian context.  
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Table 1. Socio-economic, demographic and lifestyle characteristics of the study population 
Variable 
Total 
(N=239) 
HIV or AIDS 
(N=208) 
TB/HIV 
(N=26) 
LTBI/HIV 
(N=5) 
P- 
value1 
N % N % N % N % 
Socio-economic          
Gender          
   Female 64 27 57 27 3 12 4 80 
0·007 
   Male 175 73 151 73 23 88 1 20 
Age          
   18-28 81 34 72 35 8 31 1 20 
0·906 
   29-39 75 31 63 30 10 38 2 40 
   40-50 60 25 53 25 6 23 1 20 
   ≥51 23 10 20 10 2 8 1 20 
Literate 2          
    Yes 216 90 190 91 21 81 5 100 
0·212 
    No 23 10 18 9 6 19 0 0 
Income 3          
    No income 38 16 35 17 3 12 0 0 
0·265     < Minimum wage 81 34 65 31 13 50 3 60 
    ≥ Minimum wage 120 50 108 52 10 38 2 40 
Lifestyle habits          
Smoking           
     Current 58 24 52 25 6 23 0 0 
0·034      Never 137 57 122 59 10 38 5 100 
     Former 44 18 34 16 10 38 0 0 
Alcohol 4          
     Low risk 146 61 134 64 9 35 3 60 
0·009 
     Hazardous drinking 48 20 41 20 5 19 2 40 
     Harmful drinking  18 7 14 7 4 15 0 0 
     Alcohol dependence 27 11 19 9 8 31 0 0 
Illicit drug use – last year          
Cannabis          
     Yes 20 8 16 8 3 11 1 20 
0·458 
     No 217 91 190 91 23 88 4 80 
Cocaine          
     Yes 10 4 6 3 3 12 1 20 
0·074 
     No 228 95 201 97 23 88 4 80 
Glue          
     Yes 2 1 0 0 2 8 0 0 
0·025 
     No 236 99 207 99 24 92 5 100 
Crack          
     Yes 8 3 4 2 4 15 0 0 
0·039 
     No 228 95 201 97 22 85 5 100 
1 Fisher’s exact. After exclusion of LTB/HIV patients from the analysis, only the variables smoking (p = 0·028), alcohol (p 
= 0·002), glue (p = 0·012) and crack (p = 0·009) remain statistically significant. 
2 Minimum of four years of study (mec.gov.br) 
3 Brazilian minimum wage, 2015 = US$ 251·7per month 
4 As defined by the WHO: The Alcohol Use Disorders Identification Test (AUDIT), 2011 
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Table 2. Characteristics of treatment and health outcomes for patients treated at the Correia Picanco 
Hospital, Recife/Brazil 
Variables 
HIV or Aids  
(N =208) 
TB/HIV (N = 26) LTBI/HIV (N = 5)  
Emergency care  N %  N %  N %  P- value3 
Pre-diagnosis period1        
Yes 86 41 21 81 - - 
<0·001 
No 122 59 5 19 - - 
Treatment period2 N %  N %  N %  P- value4 
Yes 112 59 19 73 - - 
0·060 
No 96 41 7 27 - - 
Hospitalisation  N %  N %  N %  P- value4 
Pre-diagnosis period        
Yes 19 8 11 42 - - 
<0·001 
No 189 92 15 58 - - 
Treatment period       P- value3 
Yes 39 19 20 77 1 20 
<0·001 
No 169 81 6 33 4 80 
Length of hospitalisation Mean SD Mean SD Mean SD P-Value5 
Pre-diagnosis period        
Days 12.4 12.2 18.3 14.2 - - 0·140 
Treatment period        
Days 18.8 17.0 28.0 22.4 - - 0·240 
CD4 count (1st appointment) N %  N %  N %  P-Value3 
>500 53 25 2 8 2 40 
0·009 
200-499 55 26 5 19 1 20 
<200 85 41 16 62 0 0 
Not informed 15 7 3 12 2 40 
First ART scheme (1st year)        
TDF+3TC+EFZ 128 61 13 50 2 40 
0·010 
AZT+3TC+EFZ 18 9 8 31 1 20 
Others 40 19 2 8 0 0 
Did not start ART 22 11 3 11 2 40 
Average days of ART - 1st 
year 
Mean SD Mean SD Mean SD P-Value5 
249 87.0 181 102.8 160 56.6 0·003 
Outcome N %  N %  N %  P-Value3 
Cure or end of follow-up 195 94 18 69 5 100 
0·001 
Death 13 6 8 31 0 0 
1 Pre-diagnosis period: onset of TB or HIV symptoms until TB, LTBI or HIV/AIDS diagnosis  
2 Treatment period: one year of treatment or death before one year for HIV or AIDS, complete TB (six to nine months) or 
LTBI (six months) treatment or death before end of treatment 
3 Fisher's exact 
4 Chi square  
5 Two-sample Wilcoxon rank-sum (Mann-Whitney) test 
 
13 
 
Table 3. Mean direct medical costs (US$) per cost category for pre-diagnosis and treatment from the public health system perspective, Correia Picanco Hospital, 
Recife/Brazil 
Cost item 
HIV or AIDS TB/HIV LTBI/HIV 
N 
Pre-diagnosis  
Mean (SD) 
N 
Treatment  
Mean (SD) 
N 
Pre-diagnosis  
Mean (SD) 
N 
Treatment  
Mean (SD) 
N 
Pre-diagnosis  
Mean (SD) 
N 
Treatment  
Mean (SD) 
Emergency care 86  112  21  19      
Drugs  1.2 (4.0)  2.0 (4.3)  45.3 (193.1)  78.9 (234.8)  -  - 
Tests  5.7 (15.0)  8.2 (14.1)  22.4 (30.1)  8.2 (11.6)  -  - 
Medical appointment  87.6 (47.5)  110.4 (89.8)  299.6 (355.8)  489.9 (1,114.7)  -  - 
Total direct medical  94·5 (53.3)  120·6 (95.0)  367.4 (540·6)  574.1 (1,334.0)  -  - 
Overhead  15.0 (8.2)  18.8 (15.4)  51.4 (59.6)  83.4 (185.8)  -  - 
Total direct medical 
and non-medical 
 109.5 (61.2)  139.4 (109.8)  418.8 (586.9)  657.4 (1,439.9)  -  - 
Outpatient care 150    26  26  5  5  
Drugs  0.1 (0.5)  15.4 (52.8)  1.7 (3.1)  45.3 (50.3)  2.3 (4.8)  7.9 (5.0) 
ART  -  467.7 (276.4)  70.9 (142.0)  261.6 (205.4)  7.4 (16.5)  140.9 (185.5) 
TB drugs  -  -  -  23.0 (17.0)  -  4.9 (0.0) 
Tests  7.8 (12.3)  61.9 (38.2)  65.0 (83.7)  45.2 (53.8)  65.5 (23.6)  65.7 (56·3) 
Medical appointment  47.0 (32.8)  195.1 (119.1)  110.8 (71.3)  262.7 (155.0)  73.7 (55.0)  328.1 (207.0) 
Total direct medical  54·8 (38.8)  740.2 (357.5)  248.5 (218.4)  637.9 (389.0)  148.8 (48.2)  547.5 (394.0) 
Overhead  8.8 (6.2)  36.7 (22.4)  20.8 (13.2)  49.4 (28.6)  13.9 (9.3)  61.7 (34.8) 
Total direct medical 
and non-medical 
 63.7 (44.7)  776.9 (369.9)  269.3 (220.4)  687.3 (406.3)  162.7 (49.9)  609.3 (383.4) 
Inpatient care 19  38  11  20  0  1  
Drugs  111.4 (161.6)  407.9 (549.2)  172.0 (172.5)  754.7 (874.7)  -  15.3 
ART  -  18.6 (37.9)  12.7 (23.7)  29.1 (36.9)  -  0.0 
TB drugs  -  -  -  3.9 (4.1)  -  0.0 
Tests  119.7 (109.9)  177.0 (184.9)  170.3 (165.1)  237.7 (201.7)  -  175.6 
Bed day  479.9 (446.9)  733.2 (617.2)  706.5 (576.1)  1,092.4 (990·8)  -  117.0 
Total direct medical  710·9 (633.4)  1,336.8 (1,265·3)  1,061.5 (870.1)  2,117.7 (1,795·1)  -  307.9 
Overhead  999.1 (930.0)  1,513.0 (1,367.0)  1,471.0 (1,143.7)  2,254.0 (1,926.6)  -  241.5 
Total direct medical 
and non-medical 
 1,710.1 (1,547.2)  2,849.8 (2,562.6)  2,532.5 (1,971.3)  4,371.7 (3,652.7)  -  549.5 
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Table 4. Total mean cost (US$) for pre-diagnosis and treatment periods from the health system perspective, 
Correia Picanco Hospital, Recife/Brazil 
Status N 
Pre-diagnosis Treatment Total 
Mean (SD) Mean (SD) Mean (SD) 
HIV or AIDS 
   Drugs 
   Tests 
   ART    
   Medical appointment/bed day 
   Overhead 
   Total 
195 
 
11.3  (60.3) 
19.3  (50.6) 
- 
114.4  (200.7) 
107.3 (413.3) 
252.4  (697.3) 
 
76.3 (277.3) 
91.9 (104.4) 
492.0 (266.7) 
373.5 (422.1) 
273.3 (800.8) 
1,306.0 (1,549·5) 
 
87.6  (286.0) 
11.3 (118.1) 
492.0 (266.7) 
487.9  (471.1) 
379.5  (899.4) 
1,558.4  (1,713.7) 
AIDS death 
   Drugs 
   Tests 
   ART 
   Medical appointment/bed day 
   Overhead 
   Total 
13 
 
1.5 (3.5) 
12.8 (33.4) 
- 
106.6  (106.9) 
52.8 (125.4) 
173.8  (231.0) 
 
344.2 (339.4) 
215.2 (133.1) 
159.3 (236.7) 
730.4 (465.9) 
1,205.5 (857.7) 
2,654.7 (1,648.6) 
 
345.8 (340.2) 
228.0  (143.7) 
159.3 (236.7) 
837.0  (526.3) 
1,258.3  (963.1) 
2,828.4  (1,833.9) 
TB/HIV 
   Drugs 
   Tests 
   ART 
   TB drugs   
   Medical appointment/bed day 
   Overhead 
   Total 
18 
 
84.0 (238.2) 
131.7 (137.9) 
81.3 (163.0) 
- 
531.6 (488.2) 
384.6 (555.4) 
1,213·2 (1,189.0) 
 
478.8 (625.5) 
209.7 (182.8) 
354.7 (171.5) 
33.0 (12.7) 
1,478.0 (1,398.2) 
1,521.7 (1,733.5) 
4,075·8 (3,558.2) 
 
562.8 (834.2) 
341.4 (243.0) 
436.0 (209.8) 
33.0 (12.7) 
2,009.6 (1,767.9) 
1,906.3 (1,864.0) 
5,289·0 (4,190.2) 
TB/HIV death 
   Drugs 
   Tests 
   ART 
   TB drugs 
   Medical appointment/bed day 
   Overhead 
   Total 
8 
 
172.1 (202.9) 
208.1 (183.5) 
65.1 (61.4) 
- 
921.7 (727.0) 
1,359.9 (1,466.7) 
2,727.0 (2,523.8) 
 
1,442.2 (1,123.3) 
289.0 (244.0) 
125.1 (177.4) 
10.1 (11.8) 
1,415.8 (1,144.0) 
2,569.9 (2,297.2) 
5,554.1 (4,591.2) 
 
1,316.4 (1,049.5) 
497.1 (203.7) 
190.2 (205.6) 
10.1 (11.8) 
2,337.5 (821.7) 
3,929.8 (1,693.8) 
8,281.0 (3,466.9) 
LTBI/HIV 
   Drugs 
   Tests 
   ART 
   TB drugs 
   Medical appointment/bed day 
   Overhead 
   Total 
5 
 
2.3 (4.3) 
65.5 (21.1) 
7.4 (14.8) 
- 
73.7 (49.2) 
13.9 (9.3) 
162.7 (49.9) 
 
10.9 (10.5) 
100.8 (117.2) 
140.9 (165.9) 
4.9 (-) 
351.6 (207.5) 
110.0 (114.5) 
719.2 (565.7) 
 
13.2 (10.1) 
166.4 (108.7) 
148.3 (168.5) 
4.9 (-) 
425.2 (233.3) 
123.9 (122.7) 
881.9 (613.1) 
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